Sanofi and IMD agree on Euro 600m drug tie-up
Sanofi-Synthelabo the French pharmaceuticals group is investing up to euro 600m in the late stage development and commercialisation of 20 cancer drugs belonging to biotechology firm Immuno Desighed
Sanofi-Synthelabo the French pharmaceuticals group is investing up to euro 600m in the late stage development and commercialisation of 20 cancer drugs belonging to biotechology firm Immuno Desighed